Share：
Share this content in WeChat
X
[Chinese][PDF]1161
• Review •
Advances in imaging features of histological subtypes of hepatocellular carcinoma
DING Zhihui  ZHU Shaocheng 

Cite this article as: DING Z H, ZHU S C. Advances in imaging features of histological subtypes of hepatocellular carcinoma[J]. Chin J Magn Reson Imaging, 2024, 15(4): 225-228, 234. DOI:10.12015/issn.1674-8034.2024.04.037.


[Abstract] In the fifth edition of the Classification of Digestive System Tumors released by the World Health Organization in 2019, the histological subtypes of hepatocellular carcinoma were divided into eight types: coarse beam-mass type, steatohepatitis type, fibrolaminoid type, sclerotic type, clear cell type, chromophobe type, lymphocyte-rich type and neutrophil-rich type. Different subtypes of hepatocellular carcinoma show different imaging features due to their histopathologic characteristics. However, there are few studies on the imaging manifestations of each subtype at home and abroad, and the clinical treatment recommendations based on histopathological subtypes are not clear. Based on this, this paper summarized the reported imaging findings and pathological features of each subtype of hepatocellular carcinoma, and discussed the existing limitations and future challenges, in order to provide more theoretical basis for improving the understanding of each subtype of hepatocellular carcinoma and clarifying the choice of treatment strategies.
[Keywords] hepatocellular carcinoma；subtypes；imaging features；magnetic resonance imaging；diagnosis

DING Zhihui1, 2   ZHU Shaocheng1, 2*  

1 Department of Medical Imaging, Zhengzhou University People's Hospital, Zhengzhou 450003, China

2 Department of Medical Imaging, Henan Provincial People's Hospital, Zhengzhou 450003, China

Corresponding author: ZHU S C, E-mail: zsc2686@163.com

Conflicts of interest   None.

Received  2024-01-05
Accepted  2024-03-21
DOI: 10.12015/issn.1674-8034.2024.04.037
Cite this article as: DING Z H, ZHU S C. Advances in imaging features of histological subtypes of hepatocellular carcinoma[J]. Chin J Magn Reson Imaging, 2024, 15(4): 225-228, 234. DOI:10.12015/issn.1674-8034.2024.04.037.

[1]
CAO X S, YANG H R, LUO X, et al. A cox nomogram for assessing recurrence free survival in hepatocellular carcinoma following surgical resection using dynamic contrast-enhanced MRI radiomics[J]. J Magn Reson Imag, 2023, 58(6): 1930-1941. DOI: 10.1002/jmri.28725.
[2]
CHONG H H, YANG L, SHENG R F, et al. Multi-scale and multi-parametric radiomics of gadoxetate disodium-enhanced MRI predicts microvascular invasion and outcome in patients with solitary hepatocellular carcinoma ≤5 cm[J]. Eur Radiol, 2021, 31(7): 4824-4838. DOI: 10.1007/s00330-020-07601-2.
[3]
LI Q, WEI Y, ZHANG T, et al. Predictive models and early postoperative recurrence evaluation for hepatocellular carcinoma based on gadoxetic acid-enhanced MR imaging[J/OL]. Insights Imaging, 2023, 14(1): 4 [2024-01-30]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826770. DOI: 10.1186/s13244-022-01359-5.
[4]
XIA Y X, ZHANG F, LI X C, et al. Surgical treatment of primary liver cancer: a report of 10 966 cases[J]. Chin J Surg, 2021, 59(1): 6-17. DOI: 10.3760/cma.j.cn112139-20201110-00791.
[5]
LI X M, YAO Q D, LIU C, et al. Macrotrabecular-massive hepatocellular carcinoma: what should we know?[J]. J Hepatocell Carcinoma, 2022, 9: 379-387. DOI: 10.2147/JHC.S364742.
[6]
NAGTEGAAL I D, ODZE R D, KLIMSTRA D, et al. The 2019 WHO classification of tumours of the digestive system[J]. Histopathology, 2020, 76(2): 182-188. DOI: 10.1111/his.13975.
[7]
MULÉ S, SERHAL A, PREGLIASCO A G, et al. MRI features associated with HCC histologic subtypes: a western American and European bicenter study[J]. Eur Radiol, 2023, 33(2): 1342-1352. DOI: 10.1007/s00330-022-09085-8.
[8]
CHAI F, MA Y T, FENG C Z, et al. Prediction of macrotrabecular-massive hepatocellular carcinoma by using MR-based models and their prognostic implications[J]. Abdom Radiol, 2024, 49(2): 447-457. DOI: 10.1007/s00261-023-04121-7.
[9]
SAKAMOTO Y, KAMIYAMA T, YOKOO H, et al. Hepatocellular carcinoma producing granulocyte colony-stimulating factor: diagnosis and treatment[J]. Int Cancer Conf J, 2018, 8(1): 12-16. DOI: 10.1007/s13691-018-0346-x.
[10]
WU L X, WANG B, CHEN Y, et al. Clinicopathological features and clinical significance of macrotrabecular-massive hepatocellular carcinoma[J]. Chin J Exp Surg, 2022, 39(10): 1869-1874. DOI: 10.3760/cma.j.cn421213-20220118-01020.
[11]
LIANG Y Y, XU F, WANG Z H, et al. A gadoxetic acid-enhanced MRI-based multivariable model using LI-RADS v2018 and other imaging features for preoperative prediction of macrotrabecular-massive hepatocellular carcinoma[J/OL]. Eur J Radiol, 2022, 153: 110356 [2024-01-28]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10811868. DOI: 10.1016/j.ejrad.2022.110356.
[12]
CHEN J, XIA C C, DUAN T, et al. Macrotrabecular-massive hepatocellular carcinoma: imaging identification and prediction based on gadoxetic acid-enhanced magnetic resonance imaging[J]. Eur Radiol, 2021, 31(10): 7696-7704. DOI: 10.1007/s00330-021-07898-7.
[13]
KITAO A, MATSUI O, ZHANG Y, et al. Dynamic CT and gadoxetic acid-enhanced MRI characteristics of P53-mutated hepatocellular carcinoma[J/OL]. Radiology, 2023, 306(2) [2024-01-28]. https://europepmc.org/article/MED/36219111. DOI: 10.1148/radiol.220531.
[14]
CHA H, CHOI J Y, PARK Y N, et al. Comparison of imaging findings of macrotrabecular-massive hepatocellular carcinoma using CT and gadoxetic acid-enhanced MRI[J]. Eur Radiol, 2023, 33(2): 1364-1377. DOI: 10.1007/s00330-022-09105-7.
[15]
LI M S, FAN Y H, YOU H Y, et al. Dual-energy CT deep learning radiomics to predict macrotrabecular-massive hepatocellular carcinoma[J/OL]. Radiology, 2023, 308(2): e230255 [2024-01-28]. https://europepmc.org/article/MED/37606573. DOI: 10.1148/radiol.230255.
[16]
MULÉ S, PREGLIASCO A G, TENENHAUS A, et al. Multiphase liver MRI for identifying the macrotrabecular-massive subtype of hepatocellular carcinoma[J]. Radiology, 2020, 295(3): 562-571. DOI: 10.1148/radiol.2020192230.
[17]
RHEE H, CHO E S, NAHM J H, et al. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications[J]. J Hepatol, 2021, 74(1): 109-121. DOI: 10.1016/j.jhep.2020.08.013.
[18]
YANG L L, WANG M, ZHU Y Y, et al. Corona enhancement combined with microvascular invasion for prognosis prediction of macrotrabecular-massive hepatocellular carcinoma subtype[J/OL]. Front Oncol, 2023, 13: 1138848 [2024-01-29]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986746. DOI: 10.3389/fonc.2023.1138848.
[19]
OLOFSON A M, GONZALO D H, CHANG M, et al. Steatohepatitic variant of hepatocellular carcinoma: a focused review[J]. Gastroenterology Res, 2018, 11(6): 391-396. DOI: 10.14740/gr1110.
[20]
CANNELLA R, BURGIO M D, BEAUFRÈRE A, et al. Imaging features of histological subtypes of hepatocellular carcinoma: implication for LI-RADS[J/OL]. JHEP Rep, 2021, 3(6): 100380 [2024-01-29]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603197. DOI: 10.1016/j.jhepr.2021.100380.
[21]
TRAPANI L, BEAUFRÈRE A, HOBEIKA C, et al. Pathological overview of steatohepatitic hepatocellular carcinoma in a surgical series[J]. Histopathology, 2023, 83(4): 526-537. DOI: 10.1111/his.14941.
[22]
SHIBAHARA J, ANDO S, SAKAMOTO Y, et al. Hepatocellular carcinoma with steatohepatitic features: a clinicopathological study of Japanese patients[J]. Histopathology, 2014, 64(7): 951-962. DOI: 10.1111/his.12343.
[23]
JAIN D. The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis[J]. Hum Pathol, 2012, 43(5): 769-770. DOI: 10.1016/j.humpath.2011.12.016.
[24]
INUI S, KONDO H, TANAHASHI Y, et al. Steatohepatitic hepatocellular carcinoma: imaging findings with clinicopathological correlation[J/OL]. Clin Radiol, 2021, 76(2): 160.e15-160.e25 [2024-01-30]. https://europepmc.org/article/MED/33046228. DOI: 10.1016/j.crad.2020.09.011.
[25]
BASARAN C, KARCAALTINCABA M, AKATA D, et al. Fat-containing lesions of the liver: cross-sectional imaging findings with emphasis on MRI[J]. AJR Am J Roentgenol, 2005, 184(4): 1103-1110. DOI: 10.2214/ajr.184.4.01841103.
[26]
LOY L M, LOW H M, CHOI J Y, et al. Variant hepatocellular carcinoma subtypes according to the 2019 WHO classification: an imaging-focused review[J]. AJR Am J Roentgenol, 2022, 219(2): 212-223. DOI: 10.2214/AJR.21.26982.
[27]
CALDERARO J, ZIOL M, PARADIS V, et al. Molecular and histological correlations in liver cancer[J]. J Hepatol, 2019, 71(3): 616-630. DOI: 10.1016/j.jhep.2019.06.001.
[28]
ABDELHAMED W, EL-KASSAS M. Fibrolamellar hepatocellular carcinoma: a rare but unpleasant event[J]. World J Gastrointest Oncol, 2022, 14(6): 1103-1114. DOI: 10.4251/wjgo.v14.i6.1103.
[29]
LEMEKHOVA A, HORNUSS D, POLYCHRONIDIS G, et al. Clinical features and surgical outcomes of fibrolamellar hepatocellular carcinoma: retrospective analysis of a single-center experience[J/OL]. World J Surg Oncol, 2020, 18(1): 93 [2024-01-30]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218513. DOI: 10.1186/s12957-020-01855-2.
[30]
GANESHAN D, SZKLARUK J, KASEB A, et al. Fibrolamellar hepatocellular carcinoma: Multiphasic CT features of the primary tumor on pre-therapy CT and pattern of distant metastases[J]. Abdom Radiol, 2018, 43(12): 3340-3348. DOI: 10.1007/s00261-018-1657-2.
[31]
ICHIKAWA T, FEDERLE M P, GRAZIOLI L, et al. Fibrolamellar hepatocellular carcinoma: imaging and pathologic findings in 31 recent cases[J]. Radiology, 1999, 213(2): 352-361. DOI: 10.1148/radiology.213.2.r99nv31352.
[32]
MULAZZANI L, ALVISI M. Imaging findings of hepatic epithelioid hemangioendothelioma and fibrolamellar hepatocellular carcinoma: a critical appraisal of current literature about imaging features of two rare liver cancers[J]. Transl Cancer Res, 2019, 8(Suppl 3): S297-S310. DOI: 10.21037/tcr.2018.11.33.
[33]
YANG X Y, WANG M L, CHEN L L, et al. Comparative analysis of the clinical manifestation and magnetic resonance imaging of scirrhous hepatocellular carcinoma and common hepatocellular carcinoma[J]. Chin J Hepatobiliary Surg, 2022, 28(8): 618-620. DOI: 10.3760/cma.j.cn113884-20220311-00101.
[34]
KIM S H, LIM H K, LEE W J, et al. Scirrhous hepatocellular carcinoma: comparison with usual hepatocellular carcinoma based on CT-pathologic features and long-term results after curative resection[J]. Eur J Radiol, 2009, 69(1): 123-130. DOI: 10.1016/j.ejrad.2007.09.008.
[35]
CHOI S Y, KIM Y K, MIN J H, et al. Added value of ancillary imaging features for differentiating scirrhous hepatocellular carcinoma from intrahepatic cholangiocarcinoma on gadoxetic acid-enhanced MR imaging[J]. Eur Radiol, 2018, 28(6): 2549-2560. DOI: 10.1007/s00330-017-5196-y.
[36]
PARK M J, KIM Y K, PARK H J, et al. Scirrhous hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging and diffusion-weighted imaging: emphasis on the differentiation of intrahepatic cholangiocarcinoma[J]. J Comput Assist Tomogr, 2013, 37(6): 872-881. DOI: 10.1097/RCT.0b013e31829d44c1.
[37]
LIU X L, LIN Z. Analysis of clinical and MRI features of clear cell hepatocellular carcinoma[J]. China Med Device Inf, 2022, 28(22): 8-10, 153. DOI: 10.15971/j.cnki.cmdi.2022.22.026.
[38]
HUANG K F, SONG J, FANG X Y, et al. Atypical imaging findings of primary clear cell hepatocellular carcinoma: a case report[J]. J Pract Med Tech, 2023, 30(7): 528-529, 533. DOI: 10.19522/j.cnki.1671-5098.2023.07.017.
[39]
LIU B, YANG X, CHEN F, et al. The value of magnetic resonance imaging in the diagnosis of clear cell hepatocellular carcinoma[J]. Chin J Magn Reson Imag, 2021, 12(5): 21-24. DOI: 10.12015/issn.1674-8034.2021.05.005.
[40]
KANG H J, OH J H, KIM Y W, et al. Clinicopathological and molecular characterization of chromophobe hepatocellular carcinoma[J]. Liver Int, 2021, 41(10): 2499-2510. DOI: 10.1111/liv.14975.
[41]
SHIN S H, PARK J Y, HWANG C, et al. Histological subtypes of hepatocellular carcinoma: their clinical and prognostic significance[J/OL]. Ann Diagn Pathol, 2023, 64: 152134 [2024-01-28]. https://europepmc.org/article/MED/37004359. DOI: 10.1016/j.anndiagpath.2023.152134.
[42]
WOOD L D, HEAPHY C M, DANIEL H D J, et al. Chromophobe hepatocellular carcinoma with abrupt anaplasia: a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features[J]. Mod Pathol, 2013, 26(12): 1586-1593. DOI: 10.1038/modpathol.2013.68.
[43]
ZHANG K, TAO C C, TAO Z G, et al. Lymphoepithelioma-like carcinoma in liver not associated with Epstein-Barr virus: a report of 3 cases and literature review[J/OL]. Diagn Pathol, 2020, 15(1): 115 [2024-01-29]. https://europepmc.org/article/MED/32967689. DOI: 10.1186/s13000-020-01035-6.
[44]
SHIH E J, CHAU I Y, YEH Y C, et al. Synchronous hepatocellular carcinoma and lymphoepithelioma-like carcinoma arising from 2 different sites of the liver: A case report[J/OL]. Medicine, 2018, 97(40): e12548 [2024-01-29]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200470. DOI: 10.1097/MD.0000000000012548.
[45]
YUAN L S, AUCEJO F, NARAYANAN MENON K V, et al. Lymphoepithelioma-like hepatocellular carcinoma: report of three cases and review of literature[J]. J Med Cases, 2015, 6(7): 297-303. DOI: 10.14740/jmc2106w.
[46]
NAGATA H, KOMATSU S, TAKAKI W, et al. Granulocyte colony-stimulating factor-producing hepatocellular carcinoma with abrupt changes[J]. World J Clin Oncol, 2016, 7(5): 380-386. DOI: 10.5306/wjco.v7.i5.380.
[47]
KOHNO M, SHIRABE K, MANO Y, et al. Granulocyte colony-stimulating-factor-producing hepatocellular carcinoma with extensive sarcomatous changes: report of a case[J]. Surg Today, 2013, 43(4): 439-445. DOI: 10.1007/s00595-012-0202-0.
[48]
AUER T A, HALSKOV S, FEHRENBACH U, et al. Gd-EOB MRI for HCC subtype differentiation in a western population according to the 5th edition of the World Health Organization classification[J]. Eur Radiol, 2023, 33(10): 6902-6915. DOI: 10.1007/s00330-023-09669-y.

PREV Value of imaging techniques in early detection and assessment of cardiac dysfunction in breast cancer patients post-chemotherapy
NEXT Progress in the application of magnetic resonance spectroscopy in Chinese medicine research
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn